Language Selector

    IMI 2 Call 9 is Launched

    Published on 02 May 2016
    Author: Marlen Damjanovic, National Contact Point Health, Demographic Change & Wellbeing

    The Innovative Medicines Initiative 2 (IMI2) Call 9 was launched on 27 April 2016 to submit project proposals.

    The IMI 2 Call 9 has now been launched with the following topics:

    • Addressing the clinical burden of Clostridium difficile infection (CDI): evaluation of the burden, current practices and set up of a European research platform (part of the IMI New Drugs for Bad Bugs (ND4BB) programme)
    • Development of immune tolerance therapies for the treatment of rheumatic diseases
    • Data quality in preclinical research and development
    • Next generation of electronic translational safety – NEXGETS
    • Identification and validation of biomarkers for non-alcoholic steatohepatitis (NASH) and across the spectrum of non-alcoholic fatty liver disease (NAFLD)
    • Joint influenza vaccine effectiveness surveillance

    The deadline for submission of proposals is 26 July 2016 - 17:00:00 Brussels time.

    More Information